Partnership Strategy


  • Is an immunotherapeutic company dedicated to the discovery and development of novel immunotherapies to treat cancer with a primary focus towards orphan diseases.
  • Intends to develop each orphan oncology drug program to the highest value inflection point possible.
  • Will seek to enter into global development and license agreements with partners in all clinical phases, either based on results from the clinical programs or other new cancer studies.
  • Is open to explore the opportunity of merging cell-based technologies to further improve the treatment based on the ALECSAT technology, or the partner technology platform.
  • Performs also animal cancer experiments (mouse models) with academic partners.
  • Is looking for partners to its COVID-19 cell-based technology treatment (patent filed January 2021).
  • Have generated much clinical information from its glioblastoma multiforme trials which can support further clinical development programs.
  • Enter partnerships with companies seeking cell-based manufacturing capacity.
ALECSAT is manufactured on the basis of a blood donation from the individual patient – without the use of advanced and expensive techniques – leading to a rapid and easy production procedure.

The Danish Cancer Society

Bárður Sigurgeirsson MD, PhD. Assistant Professor of Dermatology University of Iceland

Arkadiusz Dudek, MD, PhD Professor
University of Illinois Cancer Center

Error, cant find that post.